Toward aggregation-resistant antibodies by design.
Monoclonal antibodies are attractive therapeutics for treating a wide range of human disorders due to their exquisite binding specificity and high binding affinity. However, a limitation of antibodies is their highly variable and difficult-to-predict propensities to aggregate when concentrated during purification and delivery. Despite the large size and complex structure of antibodies, recent findings suggest that antibody solubility can be dramatically improved using rational design methods in addition to conventional selection methods. Here, we review key advances and unmet challenges in engineering the variable and constant regions of antibody fragments and full-length antibodies to resist aggregation without reducing their binding affinity. These experimental and computational discoveries should accelerate the development of robust algorithms for designing aggregation-resistant antibodies.
Center for Biotechnology & Interdisciplinary Studies, Department of Chemical & Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Christine C
CC
Lee
Joseph M
JM
Perchiacca
Peter M
PM
Tessier
D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D001688:Biological Products / Q000737:chemistry*; D006801:Humans; D011489:Protein Denaturation; D015202:Protein Engineering / Q000379:methods*; D055550:Protein Stability; D013678:Technology, Pharmaceutical / Q000379:methods*
D000911:Antibodies, Monoclonal; D001688:Biological Products
Fab; Fv; IgG; V(H); V(L); antibody engineering; bispecific; complementarity-determining region (CDR); monoclonal antibody; scFv; solubility; variable domain